17 results about "Vaccine virus" patented technology

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.

The invention discloses a bovine virus diarrhea live vaccine based on suspension culture and a preparation method thereof, and relates to the field of animal vaccines. The bovine viral diarrhea virus vaccine is a freeze-dried vaccine, and each vaccine contains a bovine viral diarrhea virus BVDV attenuated strain antigen and a freeze-drying protective agent; wherein the virus content of the antigen of the BVDV attenuated strain is 105-107 CCID50 / piece, and the BVDV attenuated strain is a cytopathic effect type attenuated strain suitable for suspension culture; the freeze-drying protective agent comprises trehalose, cane sugar, gelatin hydrolysate, sodium glutamate and polyvinylpyrrolidone. The suspension culture technology is adopted, large-scale, efficient and stable production of BVDV antigens is achieved, an optimized freeze-drying formula is combined, the obtained vaccine is high in virus titer, good in immunogenicity, high in stability, good in safety, advanced in production process, controllable in cost and suitable for industrial large-scale production.

The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.

The invention relates to an infectious spleen and kidney necrosis virus recombinant adenovirus oral preparation which is characterized by comprising the following components in percentage by mass: 2-4% of bovine serum albumin, 3-7% of lactose, 1-3% of glycine, 1-3% of mannitol, 2-4% of povidone, 1-2% of talcum powder and 0.8-3% of magnesium stearate. The balance is the cultured infectious spleen and kidney necrosis virus recombinant adenovirus liquid. The infectious spleen and kidney necrosis virus recombinant adenovirus strain is used as a vaccine virus, a wrapping agent, a protective agent and the like are added and mixed, the mixture can be added into a conventional feed, vaccine oral inoculation is achieved, the immune effect is equivalent to vaccine injection inoculation, and the vaccine has the advantages of being convenient to use, saving labor cost, reducing fish body stress loss and the like. The oral preparation disclosed by the invention is good in stability, the loss rate of active substances is low within the period of validity, and the disintegration time limit accords with national regulations.

This invention discloses PCR primers and probes for detecting ILT live vaccine virus and wild-type virus. The primers include a universal upstream primer: 5'-GCACAAAGTCCAAATCTTCT-3' and a universal downstream primer: 5'-TCAATCACAGACGGTACTTTC-3'. The probes include a vaccine virus-specific probe: 5'-FAM-CAAGTTGATGAATATGCTCAC-MGB-3' and a wild-type virus-specific probe: 5'-ROX-CAAGTTGATGAATGTGCTCA-MGB-3'. The 5' end of the vaccine virus probe is labeled with the FAM fluorescent group, and the 5' end of the wild-type virus probe is labeled with the ROX fluorescent group. The 3' ends of both probes are labeled with the MGB quencher group. Using these primers and probes, ILT live vaccine virus and wild-type virus can be detected and distinguished rapidly and accurately, and can be used for epidemic monitoring in farms.

The invention discloses a CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine and application of the CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine, and belongs to the technical field of vaccines. According to the characteristics of a natural protective antigen of the chicken anemia virus, fragments beneficial to vaccine preparation are artificially screened, after 305aa-320aa and 78aa-84aa regions with low KU645520.1 protein antigenicity are deleted, a GGGGS connecting arm is used for connection to obtain the VP1-VP2 recombinant protein, and the VP1-VP2 recombinant protein only retains a high-antigenicity core region, can be more efficiently recognized by an immune system, and has a good application prospect. The immune response intensity is enhanced; and the cross-host characteristic of the shuttle plasmid is adapted. The virus titer level of the recombinant adenovirus vector live vaccine obtained on the basis is greater than or equal to 4.74 * 10 < 10 > pfu / mL, and the immune effect on the chicken anemia virus is outstanding.

The application provides a feline calicivirus LZ-2016 strain and a vaccine composition. The feline calicivirus LZ-2016 strain has a high virus titer, the strain has strong pathogenicity to cats, and can cause typical symptoms such as oral ulcer and conjunctivitis. The inactivated product of the strain can produce a good immune response when cats are immunized, has good immunogenicity, can better stimulate the body to produce high-level neutralizing antibodies against FCV, can provide high immunoprotection rate to FCV attack, and has basic potential for developing a vaccine. The strain can be prepared into a vaccine and used for feline calicivirus prevention and treatment, provides an important vaccine virus source for feline calicivirus prevention and control in China, and realizes effective feline calicivirus prevention and control.

The present invention relates to a primer set capable of differentiating a field strain of African swine fever virus from a live vaccine virus, and a use thereof and, more specifically, to: 13 types of primer sets for conventional PCR and 12 types of primer sets for qRT-PCR capable of differentiating a field strain of African swine fever virus from a live vaccine virus; a kit for differentiating a field strain from a vaccine strain of African swine fever virus, comprising the primer sets; and a method for differentiating suids infected with a field strain of African swine fever virus from suids inoculated with a vaccine strain, using the primer sets.

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

Provided herein are isolated, non-naturally occurring, broadly reactive antigens derived from H3 (H3N2) influenza virus that are immunogenic and are capable of eliciting a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against H3 (H3N2) viruses following introduction into a subject. Also provided are non-naturally, broadly reactive occurring immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a subject by administering the isolated immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens are recombinant and comprise the hemagglutinin (HA) protein of the H3 (H3N2) influenza virus strain.

An isolated infectious bronchitis (IB) virus (IBV) QX1285 strain under accession number DPS RE RSCIC 41 in the IZSLER biobank. A vaccine comprising the isolated infectious bronchitis virus and a carrier. The virus may be inactivated. The virus may alternatively be live and attenuated. The vaccine may be formulated for an avian. The avian may be a chicken. The vaccine may be administrated via drinking water. Also claimed is an isolated infectious bronchitis virus having an S1 protein encoded by SEQ ID NO: 1 or a sequence having at least 96% sequence identity thereto, for use as a vaccine against infectious bronchitis. Also claimed is a method of vaccinating an avian against infectious bronchitis, comprising administering the vaccine. Also claimed is a process for preparing a live infectious bronchitis vaccine comprising passaging the virus to reduce pathogenicity, harvesting the attenuated virus, and processing the virus to produce a vaccine. The virus may be passaged at least 50 times. The virus may be passaged by culturing in allantoic fluid of chicken embryos.

Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.

The invention relates to the field of virology. In particular, the invention relates to a polypeptide for quantitatively detecting the HA protein of H5N1, a kit containing the polypeptide, and a method for quantitatively detecting the HA protein of H5N1 by using the polypeptide. The method is a quantitative method with high throughput, high selectivity and high sensitivity, and can be used for absolute quantification of HA protein in H5N1 vaccine virus liquid.

The present disclosure relates to sVERO 7C2, which is a Vero cell line derived from Vero cells (African Green Monkey Kidney Cell Line) distributed from the WHO and capable of suspension culture without serum components. Further, the present disclosure relates to a culture method for growing the Vero cells and a method for producing a vaccine virus using the Vero cells.

The application discloses a PCR primer and probe for identifying serum type I Marek's vaccine virus and wild virus, wherein the primer comprises an upstream primer with a sequence as shown in SEQ ID No:1 and a downstream primer with a sequence as shown in SEQ ID No:2; and the probe comprises a wild virus-specific probe with a sequence as shown in SEQ ID No:3 and a vaccine virus-specific probe with a sequence as shown in SEQ ID No:4. Through the primer and the probe, the serum type I Marek's vaccine virus and the wild virus can be efficiently, conveniently and quickly identified, so that early warning, accurate prevention and control and purification of Marek's disease are realized.

Provided herein are isolated, non-naturally occurring, widely reactive antigens derived from an H3 (H3N2) influenza virus, which antigens are immunogenic and are capable of eliciting a widely reactive immune response against the H3 (H3N2) virus, such as a widely reactive neutralizing antibody response, upon introduction into a subject. Non-naturally occurring, broadly reactive immunogens, vaccines, virus-like particles (VLPs), and compositions comprising the immunogens and vaccines are also provided. Methods of generating an immune response in a subject by administering the isolated immunogen, vaccine, VLP, or a composition thereof are provided. In particular, the immunogen is recombinant and includes a hemagglutinin (HA) protein of an H3 (H3N2) influenza virus strain.

The invention discloses a freeze-drying protective agent of an infectious laryngotracheitis recombinant fowlpox virus genetic engineering vaccine as well as a preparation method and application of the freeze-drying protective agent, and belongs to the technical field of veterinary biological products. In order to reduce the virus loss of the avian infectious laryngotracheitis recombinant fowlpox virus genetic engineering vaccine in the freeze-drying process and improve the virus titer, different freeze-drying protective agent formulas and freeze-drying curves are screened, and a freeze-drying protective agent capable of reducing the virus loss of the vaccine and a matched freeze-drying process of the freeze-drying protective agent are successfully developed. The screened freeze-drying protective agent and freeze-drying curve can reduce the virus loss of the avian infectious laryngotracheitis recombinant fowlpox virus genetic engineering vaccine in the freeze-drying process, greatly improve the feather quantity contained in each bottle of vaccine, and ensure the stability of the vaccine during the vaccine storage period; the production cost can be reduced while the vaccine quality is improved, and actual production requirements are met.